Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine

Journal of Virology

Volumn 76, Issue 15, 2002, Pages 7832-7842

  Emeny, Rebecca T ^a   Wheeler, Cosette M ^a   Jansen, Kathrin U ^a   Hunt, William C ^a   Fu, Tong Ming ^a   Smith, Judith F ^a   MacMullen, Stefani ^a   Esser, Mark T ^a   Paliard, Xavier ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGING; ANTIBODY SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; TISSUE SPECIFICITY; VIRUS PARTICLE; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN ISOTYPES; LYMPHOCYTE ACTIVATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TH1 CELLS; TH2 CELLS; TUMOR VIRUS INFECTIONS; VIRAL VACCINES; VIRION;

EID: 0036317770     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.15.7832-7842.2002     Document Type: Article

References (56)

1. Phenotypic analysis of antigen-specific T lymphocytes
2. Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions
3. Human papillomavirus type 16. E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia
4. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
5. Detection of multiple human papillomavirus types in condylomata acuminata lesions from othenvise healthy and immunosuppressed patients
6. Neutralization of human papillomavirus type 11 (HPV11) by serum from women vaccinated with yeast-derived HPV11 virus-like particles: Correlation with competitive radioimmunoassay titer
7. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
8. Cytokine production patterns in cervical intraepithelial neoplasia: Association with human papillomavirus infection
9. Immunological events in regressing genital warts
10. L1 specific protection from tumor challenge elicited by HPV16 virus-like particles
11. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome
12. Induction of rabies virus-specific T-helper cells by synthetic peptides that carry dominant T-helper cell epitopes of the viral ribonucleoprotein
13. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers
14. Lymphocyte lifespans: Homeostasis, selection and competition
15. Evaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian human immunodeficiency virus
16. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts
17. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins
18. Human papillomavirus and lower genital tract neoplasia in renal transplant patients
19. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
20. Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes
21. Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts
22. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation
23. Studies on vaccination against papillomaviruses: The immunity after infection and vaccination with bovine papillomaviruses of different types
24. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: Outcome of HPV infection and associated neoplasia
25. Cellular immunity against human papillomavirus associated cervical cancer
26. + responses
27. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
28. Anal human papillomavirus infection among HIV-seropositive and negative men
29. Epidemiology of genital human papillomavirus infection
30. Papillomavirus-like particles induce acute activation of dendritic cells
31. Mucosal immunization with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice
32. Human papillomavirus type II (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast
33. The dynamics of the cellular immune response to HIV infection: Implications for vaccination
34. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women
35. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte responses to the E6 antigens
36. The cellular immune system in female patients with or without genital warts: A study of peripheral white blood components
37. + cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques
38. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles
39. Human papillomavirus type 6b virus-like particles are able to activate the Ras-MAP kinase pathway and induce cell proliferation
40. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway
41. Cytotoxic t-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
42. Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity
43. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine
44. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles
45. Human papillomavirus infections in a group of renal transplant recipients
46. + lymphocytes
47. Proliferative T cell responses to the human papillomavirus type 16 L1 peptides in patients with cervical dysplasia
48. T-cell responses to human papillomavirus in cervical dysplasia
49. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques
50. Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions
51. Expression in Escherichia coli of seven DNA fragments comprising the complete L1 and L2 open reading frames of human papillomavirus type 6b and localization of the 'common antigen' region
52. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
53. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: Correlation with cervical pathology
54. Multiplexed particle-based flow cytometric assays
55. HPV6b virus-like particles are potent immunogens without adjuvant in man
56. Viruses in human cancer